myNEO Therapeutics
Founded 2018 · 18 employees on LinkedIn · 1 known investors
Find your way into myNEO Therapeutics
myNEO provides AI-powered software for drug discovery and development, specifically targeting antibody, bispecific, ADC, cell therapy, vaccine, and neoantigen-based immunotherapy programs. The company serves pharmaceutical and biotech organizations across target discovery, optimization, and data analysis stages.
Founders & leadership
Board
CB
Cedric BogaertinEntrepreneur in Residence - managing myNEO at Novalis Biotech
JV
Jan Van Den BergheinCo-Founder / Managing Director at Novalis Biotech
WV
Wim van CriekingeinCo-Founder / Managing Director at Novalis Biotech
Investors · 1
Frequently asked questions
- What does myNEO Therapeutics do?
- myNEO provides AI-powered software for drug discovery and development, specifically targeting antibody, bispecific, ADC, cell therapy, vaccine, and neoantigen-based immunotherapy programs. The company serves pharmaceutical and biotech organizations across target discovery, optimization, and data analysis stages.
- Who are myNEO Therapeutics's investors?
- myNEO Therapeutics's investors include Novalis Biotech.